Cargando…
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
Autores principales: | Haberman, Rebecca H, Um, Seungha, Axelrad, Jordan E, Blank, Rebecca B, Uddin, Zakwan, Catron, Sydney, Neimann, Andrea L, Mulligan, Mark J, Herat, Ramin Sedaghat, Hong, Simon J, Chang, Shannon, Myrtaj, Arnold, Ghiasian, Ghoncheh, Izmirly, Peter M, Saxena, Amit, Solomon, Gary, Azar, Natalie, Samuels, Jonathan, Golden, Brian D, Rackoff, Paula, Adhikari, Samrachana, Hudesman, David P, Scher, Jose U |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975261/ https://www.ncbi.nlm.nih.gov/pubmed/35403000 http://dx.doi.org/10.1016/S2665-9913(22)00069-8 |
Ejemplares similares
-
Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
por: Haberman, Rebecca, et al.
Publicado: (2020) -
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2021) -
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
por: Haberman, Rebecca H, et al.
Publicado: (2022) -
COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study
por: Yan, Di, et al.
Publicado: (2022) -
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City
por: Saxena, Amit, et al.
Publicado: (2022)